Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells

Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by in silico screening in non-small cell lung cancer cells. Mitoxantrone can suppress the phosphorylation of ROS1 and subsequently inhibit its...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Medchemcomm
Autori principali: Luo, Lian-Xiang, Fan, Xing-Xing, Li, Ying, Peng, Xia, Ji, Yin-Chun, Hsiao, Wendy Wen-Luan, Liu, Liang, Leung, Elaine Lai-Han, Yao, Xiao-Jun
Natura: Artigo
Lingua:Inglês
Pubblicazione: Royal Society of Chemistry 2017
Soggetti:
Chemistry
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6071735/
https://ncbi.nlm.nih.gov/pubmed/30108778
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1039/c6md00643d
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi